The aim of present is to develop and evaluate extended release matrix tablet of Valsartan. Valsartan is an Hypotensive agents. But owing to its shorter half life it needs frequent administration. In present study, an attempt has been made to develop extended release matrix tablet of Valsartan there by reducing its frequency of administration and other dose related side effects. Different types of Eudragit S 100, Sodium CMC and HPMC K4M were used as polymers. Total 12 formulations were prepared in trial batches. The formulation was evaluated for various pre compression and post compression parameters. All the formulations showed compliance with the pharmacopoeial standards. On the basis of evaluated parameters formulation V8 was considered to be the best one. Formulation V8 containing polymer Sodium CMC showed 98.53 percent invitro drug release profile. The release data for formulation V8 was fitted to various mathematical models like zero order, first order, Krosmeyer Peppas and Higuchi model. It was observed that drug follows Peppas release mechanism.